The immune therapy registry is an exciting new project from the IMF’s research division the IMWG. The project has been established in collaboration with global investigators and pharmaceutical industry partners.
Please note that Ask Dr. Durie has been discontinued, and it was designed to address myeloma questions of the broadest possible audience interest. If you have a question of a personal nature, please contact our InfoLine Coordinators at 800.452.2873 or [email protected] (Please do not send email attachments or lab reports.).
This week’s “Ask Dr. Durie” comes from who has learned that an immune therapy registry is being started.
And so, the first answer to this question is to say that they are correct in that there is an immune registry being started. This is a project from the International Myeloma Working Group, the research division of the IMF.
And so, this immune therapy registry is being established and co-led by investigators Dr. Tom Martin from the University of California in San Francisco and Dr. Yi Lin from the Mayo Clinic in Rochester, Minnesota. And what they have set out to do is gather data for patients receiving immune therapies that have been approved by the FDA.
And so, what this is, is a real-world registry. What’s called a real-world registry. It’s going to be capturing information about the benefit and possible side effects or toxicities of therapies in a community setting for patients who are being treated by their own local doctors and to gather up that information in a sequential and ongoing fashion so that we can understand how these treatments are working in the real-world situation and what, if any, difficulties might be emerging from the use of these exciting new therapies.
And so, the initial idea is to study belantamab, the CAR T therapies, the Abecma®, as well as cilta-cel, and once approved by the FDA, the bispecific antibodies.
And so, the BOTTOM LINE is that this immune therapy registry which will be housed in a computer format at the University of California San Francisco will gather this important real-world data which will be a resource for everyone for investigators around the world and for pharma partners to understand how do these different therapies work? And, particularly, what could be the best sequencing of these drugs? Is it better to give one before or after the other? And does it affect the outcomes or toxicities? And so, we’re excited that this is an important resource for patients and for investigators on a global basis.
Dr. Brian G.M. Durie (1942-2025) was the co-founder of the IMF. He was a Professor of Medicine, Hematologist/Oncologist, and Honoree MD at the University of Brussels.
